Status:
COMPLETED
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
Lead Sponsor:
Arianna Anticoagulazione Foundation
Conditions:
Atrial Fibrillation
Anticoagulant-induced Bleeding
Eligibility:
All Genders
18+ years
Brief Summary
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Ita...
Detailed Description
The MAS Study is an observational, prospective cohort study, double blind, multicentre, international and no Profit. Anticoagulation clinics, affiliated or not to the Italian FCSA, will be asked to ta...
Eligibility Criteria
Inclusion
- NVAF patients starting DOAC anticoagulation
- age \> 18 years
- ability to give written informed consent
- availability, as part of the normal withdrawals, to the blood sampling for the study purpose
- availability for 12-months follow-up
Exclusion
- age \< 18 years
- indication for electrical cardioversion at the moment of drug prescription
- participation in Phase II or III clinical trials
- indication for treatment different from NVAF
- not suitable to give or not giving informed consent
- not available for blood collection or follow-up
Key Trial Info
Start Date :
August 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2023
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03803579
Start Date
August 9 2018
End Date
May 30 2023
Last Update
July 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sophie Testa
Cremona, Italy, 26100